# The 340B Drug Pricing Program: The Hundred-Billion-Dollar Discount That Costs Taxpayers Almost Nothing

340B moved roughly 100 billion dollars in discounted drug purchases in 2025 while costing taxpayers almost nothing. Here is how safety-net providers keep the spread.

Author: J.A. Watte
Published: July 16, 2026
Source: https://jwatte.com/blog/340b-drug-pricing-program/

---


There is a federal drug program that moved something on the order of 100 billion dollars in purchases in a single year, is fought over in half a dozen federal courts, and yet appears almost nowhere in the federal budget, because it spends almost none of the government's money. It is not an appropriation. Congress did not write a check. Instead, in a single 1992 statute, it ordered drug manufacturers to sell certain drugs to certain hospitals and clinics at a deep discount, and then let those providers do the rest. The providers buy low, bill insurers and Medicare at the ordinary rate, and keep the difference. Whether that difference is a lifeline for the poor or a windfall for large hospital systems is one of the most genuinely contested questions in American health-care finance, and the honest answer is that nobody can fully prove it either way. The program is called 340B, and understanding it means first understanding that the giant number attached to it is not money the government spent.

## What it is, and who actually runs it

The 340B Drug Pricing Program was created by the Veterans Health Care Act of 1992, which added a new Section 340B to the Public Health Service Act. It is administered by the Health Resources and Services Administration, HRSA, an agency inside the Department of Health and Human Services, specifically through its Office of Pharmacy Affairs. The statutory origin is uncontested and documented the same way across the Congressional Research Service, the Congressional Budget Office, the Government Accountability Office, and mainstream explainers [such as the Commonwealth Fund's](https://www.commonwealthfund.org/publications/explainer/2025/aug/340b-drug-pricing-program-how-it-works-and-why-its-controversial).

The mechanism is the part most people get wrong, so it is worth stating carefully. 340B is a mandated manufacturer discount, not a federal outlay. As a condition of having its drugs covered under Medicaid and Medicare Part B, a manufacturer must sign a Pharmaceutical Pricing Agreement and agree to sell its covered outpatient drugs at or below a discounted ceiling price to registered providers. The cost of the discount is borne by the manufacturer, not the Treasury. The Congressional Budget Office describes it exactly this way, [as a manufacturer-borne price ceiling rather than government spending](https://www.cbo.gov/publication/61730). That single distinction is the entire reason a program this large can hide in plain sight: there is no spending line to cut, because there is no spending.

The providers that qualify are called covered entities, and the statute defines them narrowly. There are six hospital categories: disproportionate share hospitals, children's hospitals, freestanding cancer hospitals, sole community hospitals, rural referral centers, and critical access hospitals. Alongside them sit a set of federal grantee clinics: federally qualified health centers, Ryan White HIV and AIDS clinics, family planning clinics, black lung clinics, and hemophilia treatment centers, among others. The category list matches the descriptions in [the Congressional Research Service's overview](https://www.congress.gov/crs-product/R48696), and eligibility is not automatic. Hospitals in particular have to clear ownership and disproportionate-share-adjustment tests, so not every hospital qualifies.

Congress said plainly what it was after. The 1992 House report described the purpose as letting these providers "stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services." That phrase, from H.R. Rep. No. 102-384, is quoted by HRSA, by the courts, and by advocates on both sides of every 340B fight. It is worth noting one thing the phrase does not say: it does not require an entity to pass any particular discount along to any individual patient. That silence is the seed of the whole controversy, and we will return to it.

## Where the money goes: the spread

Here is the actual engine. A covered entity buys a drug at the 340B ceiling price, which can run substantially below the ordinary market price. It then dispenses that drug to an insured patient and gets reimbursed by a commercial insurer or by Medicare at that payer's normal rate, which is far higher than the discounted price the entity paid. The entity keeps the gap. In the trade this gap is called the spread, and it is not a loophole. It is the designed source of the program's benefit. Congress never appropriated money for safety-net care through 340B; it created a discount and let the reimbursement system convert that discount into revenue.

That the spread is real and large is not a matter of advocacy. The Medicare Payment Advisory Commission, MedPAC, [studied 340B ceiling prices against Medicare reimbursement](https://www.medpac.gov/wp-content/uploads/2023/10/340B-ceiling-prices-April-2024-SEC.pdf) and found that Medicare Part B payment, historically the drug's average sales price plus 6 percent, ran well above what 340B hospitals actually paid to acquire the drug. The Government Accountability Office, the HHS Office of Inspector General, and academic researchers at the University of Southern California's Schaeffer Center have all documented the same gap. The Schaeffer analysis frames the resulting behaviour bluntly as [misaligned incentives](https://schaeffer.usc.edu/research/misaligned-incentives-340b/): when the profit on a drug rises with the drug's list price, entities have a reason to favour expensive specialty drugs and to bring more prescribing sites under the 340B umbrella.

The government has tried, once, to claw the Medicare spread back, and lost. From 2018 through 2022, the Centers for Medicare and Medicaid Services cut what Medicare paid hospitals for 340B-acquired drugs from average sales price plus 6 percent down to average sales price minus 22.5 percent, on the theory that Medicare should not overpay for drugs the hospital bought cheaply. In 2022 the Supreme Court struck the cut down in AHA v. Becerra, 142 S. Ct. 1896, holding the agency had not followed the required process. CMS then had to make hospitals whole. Its November 2023 final rule set [a one-time lump-sum remedy of 9.0 billion dollars](https://www.cms.gov/newsroom/fact-sheets/hospital-outpatient-prospective-payment-system-opps-remedy-340b-acquired-drug-payment-policy) for the years the cut was in effect, effective in January 2024. It is worth being precise that this was a single make-up payment for 2018 through 2022, not an ongoing subsidy.

How big is the discount itself? The cleanest illustration comes from comparing the discounted total against list prices, though the list-price figure is an industry estimate and should be read as illustrative, not as money anyone spent. For 2022, when covered entities bought about 53.7 billion dollars of drugs at 340B prices, the pharmaceutical-data firm IQVIA [estimated the same drugs' list-price, or wholesale acquisition cost, value at roughly 106 billion dollars](https://www.drugchannels.net/2023/09/exclusive-340b-program-reached-54.html), reported through the industry-aligned newsletter Drug Channels. Treat that gap as a rough measure of the discount's magnitude, roughly half off at list, and nothing more. IQVIA and Drug Channels sit on the pharmaceutical-supply-chain side of the debate, and the 106 billion figure is an estimate, not an audited number.

## How a modest program became a hundred-billion-dollar flow

The growth is the story. Track the throughput, always remembering it is purchases at 340B prices and not federal spending, and the trajectory is steep and recent. Covered entities bought about [43.9 billion dollars of drugs at 340B prices in 2021 and about 53.7 billion in 2022](https://340breport.com/340b-drug-purchases-reached-53-7-billion-in-2022-hrsa-data-show/), figures reported from HRSA data by 340B Report. The total reached [about 66.3 billion dollars in 2023](https://www.drugchannels.net/2024/10/the-340b-program-reached-66-billion-in.html), then about 81.4 billion in 2024, [where disproportionate share hospitals alone accounted for roughly 64.1 billion, about 78 percent of the program, and all hospitals together for about 87 percent](https://www.hrsa.gov/opa/updates/2024-340b-covered-entity-purchases). And in July 2026, HRSA's 2025 data landed at [roughly 100 billion dollars, up about 23 percent again](https://www.drugchannels.net/2026/07/the-340b-program-hit-100-billion-in.html). Five years, and the annual flow more than doubled, growing more than 22 percent nearly every year. The concentration matters as much as the size: this is overwhelmingly a large-hospital program by dollar volume, not a small-clinic one, even though small clinics are among the entities Congress named first.

What lit the fuse was not a law but a piece of sub-regulatory guidance. A covered entity often has no pharmacy of its own, so the statute lets it contract with an outside pharmacy to dispense 340B drugs on its behalf. Before 2010, HRSA guidance generally allowed one such contract pharmacy per entity. In 2010, HRSA issued new guidance permitting an effectively unlimited number of contract-pharmacy arrangements, [as the Congressional Research Service documents](https://crsreports.congress.gov/product/pdf/LSB/LSB11163). That single change let a hospital or clinic plug into national retail chains, and the number of dispensing locations exploded, drawing CVS, Walgreens, and the pharmacy-benefit managers that take a cut into a program originally imagined as safety-net providers filling their own patients' prescriptions.

The modern twist, and a correction to the usual telling, is that the contract-pharmacy count is now shrinking, not still exploding. As of mid-2026 there were about 31,593 unique contract-pharmacy locations, [down from about 32,069 a year earlier, the fourth consecutive annual decline](https://www.drugchannels.net/2026/06/the-340b-contract-pharmacy-market-in.html), driven by the retail-pharmacy shakeout and by manufacturers pulling back access. The 2010-to-early-2020s explosion is history; the current phase is contraction on top of a very large base, spread across more than 50,000 covered-entity sites, though exact site counts vary with how parent entities and child sites are tallied.

## The manufacturer war, in two separate courtrooms

Starting in 2020, drug manufacturers stopped simply complaining about contract pharmacies and began unilaterally restricting 340B pricing through them, citing drug diversion and duplicate discounts, meaning cases where a drug gets both a 340B discount and a separate Medicaid rebate. By 2026 [roughly thirty to forty-plus manufacturers had imposed some restriction](https://340breport.com/trackers/contract-pharmacy-restrictions-tracker/), a count that keeps shifting, so it is best read off the live tracker rather than fixed. Covered entities called the restrictions unlawful self-help. The manufacturers called them a lawful condition on distribution. Both went to court, and the resulting litigation splits into two tracks that are easy to conflate and important to keep apart.

The first track is the manufacturers' own unilateral restrictions, and here the manufacturers are winning at the federal appeals level. In May 2024 the D.C. Circuit held, in Novartis Pharmaceuticals Corp. v. Johnson, No. 21-5299, decided May 21, 2024, that Section 340B does not prohibit manufacturers from imposing conditions such as contract-pharmacy limits on how they distribute discounted drugs, [rejecting HRSA's contrary position](https://law.justia.com/cases/federal/appellate-courts/cadc/21-5299/21-5299-2024-05-21.html). The court left a door open, noting that more onerous conditions might still violate the statute, but the core holding went against the government. The Third Circuit reached a compatible result. HRSA's stance that manufacturers may not restrict distribution did not win.

The second track is different: state laws that force manufacturers to keep supplying contract pharmacies. Several states passed them, and until early 2026 the appeals courts had upheld them. Both the Eighth Circuit, on Arkansas's Act 1103, and the Fifth Circuit, on a Louisiana law, sided with the states, and the Supreme Court declined to hear a pharmaceutical-industry challenge to the Arkansas law in December 2024. Then on March 31, 2026, the Fourth Circuit became the first appeals court to block one, striking down West Virginia's law in a 2-to-1 decision on preemption grounds, [creating the circuit split now widely expected to reach the Supreme Court](https://www.druganddevicelawblog.com/2026/04/next-stop-scotus-fourth-circuit-creates-split-on-340b-contract-pharmacies.html). Hospital groups sought further review in April 2026, and the Justice Department entered the fray in February 2026 with briefs supporting manufacturers against other states' access laws. As of this writing there is no settled nationwide rule.

There is one more recent front. HRSA and the manufacturers have also fought over whether the 340B benefit can be delivered as a back-end rebate instead of an up-front discount, which would let manufacturers charge full price first and pay entities back later. In February 2026 a federal court in Maine, in AHA v. Kennedy, No. 25-cv-600, decided February 10, 2026, [vacated HRSA's rebate-model pilot on procedural grounds](https://natlawreview.com/article/340b-rebate-model-pilot-program-effectively-ends-preserving-upfront-discounts-now), and HHS opened a request for information to reconsider its approach. For now, the up-front discount stands.

## Why it looks like a loss

Judge 340B against its own 1992 rationale and the gaps are real. The program was sold as a way to stretch scarce dollars for the safety net, yet its dollar volume is dominated by large disproportionate-share hospitals, about 78 percent of purchases in 2024, not by the small clinics Congress named. The 2010 contract-pharmacy guidance pulled for-profit retail chains and pharmacy-benefit managers into the flow, each taking a margin, which is hard to square with stretching resources for the poor. And the incentive structure, as MedPAC and the Schaeffer researchers describe it, rewards buying more high-cost drugs and standing up more eligible prescribing sites, because the spread grows with the drug's price and with the number of sites.

The deepest problem is accountability, and here the government's own auditor is the most credible critic. In a report issued in October 2025, [the Government Accountability Office found HRSA's oversight thin](https://www.gao.gov/products/gao-26-108784): the agency audits only about 200 covered entities a year, roughly 160 of them hospitals, out of a program with tens of thousands of sites; it does not fully verify compliance with the ban on duplicate discounts; and, crucially, it cannot confirm that the savings reach patients. HRSA had implemented only 5 of the GAO's 20 recommendations. A separate GAO review had already flagged [weaknesses at the Medicaid duplicate-discount intersection](https://www.gao.gov/products/gao-20-212). The honest caveat cuts the other way too: the GAO documents gaps and unverifiable claims, not proven fraud. It has not quantified diversion, and its findings are about weak assurance, not established abuse.

Which brings the critique to its sharpest point. Because the statute never required entities to pass the discount to any individual patient, there is no reliable evidence that a low-income or uninsured person pays less at the pharmacy counter because their prescription ran through 340B. The money is real. The public benefit is asserted. The link between them is exactly what nobody can currently prove.

## Ratio-adjusted for who it serves

Now change the measure, and the defense is just as serious. Start with the fact that anchors everything: 340B costs taxpayers essentially nothing. It is a manufacturer-borne discount, not an appropriation, so the hundred-billion-dollar figure is purchasing power redirected from drug companies to safety-net providers, not a line the government could spend elsewhere. There is no budget trade-off in the ordinary sense. Every dollar of discount that a provider captures is a dollar that funds care without a dollar of federal outlay.

And for a large share of the entities Congress named, that captured spread is not a bonus, it is a margin of survival. A federally qualified health center, a Ryan White clinic, a hemophilia treatment center, or a small rural critical access hospital typically operates on the thinnest of budgets, serving patients who cannot pay and providing services Congress never fully funds. Hospital and health-center groups, the American Hospital Association, 340B Health, and the community health center associations, argue that the savings are reinvested across the whole community, through free or discounted drugs, extended clinic hours, and care for the uninsured, rather than handed back drug by drug at the counter. That, they say, is precisely the "stretch scarce federal resources" purpose Congress wrote in 1992, which spoke of reaching more patients and providing more services, not of a per-prescription rebate. These groups are advocates, not neutral parties, but the structural point stands: the program was built to fund the provider, and through the provider the community.

The contract-pharmacy fight looks different from this angle too. A small rural clinic with no pharmacy of its own reaches the 340B discount only through an outside pharmacy. When a manufacturer cancelled contract-pharmacy access, the entities that felt it most were exactly the small and rural providers that lack the in-house dispensing the large hospitals have. That is why hospital groups frame manufacturer restrictions not as trimming waste from big systems but as severing the one channel through which the smallest providers actually reach the benefit. The same neutral explainers that lay out the critics' case, [the Commonwealth Fund's among them](https://www.commonwealthfund.org/publications/explainer/2025/aug/340b-drug-pricing-program-how-it-works-and-why-its-controversial), are careful to present this defense as equally cited and equally contested, because the evidence does not clearly settle it.

## The systems behind the spread, and their investment portfolios

There is one more layer to the who-benefits question, and it connects 340B to a pattern this series has traced across other tax-exempt institutions. The largest 340B beneficiaries are not small clinics. They are big disproportionate-share hospital systems, and many of those systems are nonprofit organizations that sit on very large investment portfolios and earn substantial returns from the markets, in strong years more than they earn from treating patients.

The scale is not subtle. Nonprofit hospital systems collectively held more than 283 billion dollars in stocks, hedge funds, private equity, and venture funds as of 2019 ([KFF Health News](https://kffhealthnews.org/health-industry/mission-and-money-clash-in-nonprofit-hospitals-venture-capital-ambitions/)). Kaiser Permanente, one of the largest, reported net income of about 9.3 billion dollars in 2025, the bulk of it from investment gains rather than operations, on operating income of only about 1.4 billion, atop a reserve of cash and investments of roughly 73 billion dollars ([Becker's Hospital Review](https://www.beckershospitalreview.com/finance/kaiser-permanentes-9-3b-net-income-draws-scrutiny-six-things-to-know/)). Ascension has reported around 15.5 billion dollars in unrestricted cash and investments and runs one of the largest venture-capital funds of any nonprofit health system, above a billion dollars ([KFF Health News](https://kffhealthnews.org/health-industry/mission-and-money-clash-in-nonprofit-hospitals-venture-capital-ambitions/)). These are the kinds of institutions that capture the largest share of the 340B spread, and in a good market year the investment gains dwarf the operating margin. It is the same structure the site has described elsewhere as [institutional money that behaves like an endowment](/blog/how-deathless-money-invests/): a tax-exempt organization whose reserves, invested in the same markets as any fund, throw off returns that can exceed the surplus from its actual mission.

This is where the 340B debate gets sharpest, and it deserves both sides. Critics look at a wealthy nonprofit system with tens of billions in investments capturing a drug discount meant for the safety net and see a program drifting from its purpose. Defenders answer that the discount and the reserves together fund the charity care, the unprofitable service lines, and the community programs a thin operating margin could never support, and that a large reserve is prudence for an organization that cannot raise equity and must self-fund every expansion. Both are describing the same fact: the money is real, it is large, and much of it accrues to institutions that are, financially, closer to investment funds with hospitals attached than to the struggling clinics the program's name evokes.

That distinction is the crucial one, and it cuts against lumping every 340B entity together. The wealthy-system-with-a-portfolio description does not fit the small, fragile [Critical Access Hospital](/blog/critical-access-hospitals-rural-medicare/) that qualifies for 340B and has almost nothing in reserve, nor the [community health center](/blog/federally-qualified-health-centers/) living grant to grant. The program covers both the billion-dollar system and the county hospital one bad quarter from closing, which is why any honest read of 340B has to say which kind of entity it is describing.

## The ledger reading

340B is a program you can describe honestly as a costless public good and just as honestly as an unaccountable subsidy, because the two verdicts answer two different questions. Measured as government spending, it is close to free, a hundred billion dollars of redirected manufacturer discounts that never touch the Treasury, which is why it survives budget seasons that gut programs many times smaller. Measured as targeted help for poor patients, it is unproven, because the statute never required the savings to reach any patient and the government's own auditor cannot confirm that they do.

What makes it durable is the same thing that makes it hard to reform: the money moves through a discount rather than a check, so there is no appropriation to cut, no obvious sponsor to embarrass, and no single number a critic can point to and call waste, only a flow that is technically manufacturers' money spent under a federal mandate. The fights, accordingly, have migrated from the budget to the courts, where manufacturers, hospitals, states, and the federal government now contest who can restrict what, and whether the benefit comes up front or as a rebate, with a circuit split on state access laws likely bound for the Supreme Court. The lesson underneath is the one that recurs wherever public purpose is delivered through private plumbing. When you fund a goal by ordering someone else to eat a discount rather than by spending money directly, you get a program that is cheap, large, and nearly impossible to audit all at once, and the question of whether it does what it was meant to do becomes, permanently, a matter of which number you decide to look at.

## Related reading

- [Critical Access Hospitals and the Rural Medicare Bargain](/blog/critical-access-hospitals-rural-medicare/): the small rural hospitals that are both a 340B covered-entity category and a public-money story of their own.
- [Federally Qualified Health Centers](/blog/federally-qualified-health-centers/): the grantee clinics that were among 340B's first intended beneficiaries, read as their own funding structure.
- [How Deathless Money Invests](/blog/how-deathless-money-invests/): the institutional-money pattern behind the big nonprofit systems that capture the 340B spread and run tens of billions in market investments.

## Fact-check notes and sources

- **Created by the Veterans Health Care Act of 1992, which added Section 340B to the Public Health Service Act; administered by HRSA's Office of Pharmacy Affairs; a mandated manufacturer discount and not a federal appropriation:** the [Commonwealth Fund explainer](https://www.commonwealthfund.org/publications/explainer/2025/aug/340b-drug-pricing-program-how-it-works-and-why-its-controversial) and the [Congressional Budget Office](https://www.cbo.gov/publication/61730), which describes the program as a manufacturer-borne price ceiling rather than government spending. HRSA's own program pages sit at [hrsa.gov/opa](https://www.hrsa.gov/opa) and [hrsa.gov/opa/eligibility-and-registration](https://www.hrsa.gov/opa/eligibility-and-registration).
- **The six hospital categories plus the federal grantee clinics, and the 1992 "stretch scarce federal resources" purpose (H.R. Rep. No. 102-384), which does not require passing savings to individual patients:** the [Congressional Research Service overview](https://www.congress.gov/crs-product/R48696).
- **The spread mechanic, and Medicare Part B reimbursement (average sales price plus 6 percent) exceeding 340B acquisition cost:** the [Medicare Payment Advisory Commission analysis of 340B ceiling prices](https://www.medpac.gov/wp-content/uploads/2023/10/340B-ceiling-prices-April-2024-SEC.pdf) and the University of Southern California [Schaeffer Center](https://schaeffer.usc.edu/research/misaligned-incentives-340b/) (an academic source describing the incentives as misaligned).
- **The 2018 to 2022 Medicare cut to average sales price minus 22.5 percent, struck down in AHA v. Becerra (2022), and the one-time 9.0 billion dollar lump-sum remedy for those years:** the [CMS remedy fact sheet](https://www.cms.gov/newsroom/fact-sheets/hospital-outpatient-prospective-payment-system-opps-remedy-340b-acquired-drug-payment-policy) and the [November 2023 Federal Register final rule](https://www.federalregister.gov/documents/2023/11/08/2023-24407/medicare-program-hospital-outpatient-prospective-payment-system-remedy-for-the-340b-acquired-drug).
- **The throughput series, always purchases at 340B prices and not federal spending: about 43.9 billion (2021) and 53.7 billion (2022), 66.3 billion (2023), 81.4 billion (2024, with disproportionate share hospitals about 64.1 billion or 78 percent), and roughly 100 billion (2025):** [340B Report on the 2022 figure](https://340breport.com/340b-drug-purchases-reached-53-7-billion-in-2022-hrsa-data-show/); [Drug Channels on 2023](https://www.drugchannels.net/2024/10/the-340b-program-reached-66-billion-in.html) (an industry-aligned source reporting HRSA data via FOIA); [HRSA's 2024 update](https://www.hrsa.gov/opa/updates/2024-340b-covered-entity-purchases) and its [2023 update](https://www.hrsa.gov/opa/updates/2023-340b-covered-entity-purchases); and [Drug Channels on the 2025 hundred-billion figure](https://www.drugchannels.net/2026/07/the-340b-program-hit-100-billion-in.html), published July 2026, the latest full-year number as of writing. HRSA figures are throughput, not appropriated spending.
- **The IQVIA list-price (wholesale acquisition cost) estimate of about 106 billion dollars for 2022, against the 53.7 billion discounted total:** [IQVIA via Drug Channels](https://www.drugchannels.net/2023/09/exclusive-340b-program-reached-54.html). This is an industry estimate, used only to illustrate the discount's magnitude, never as money spent.
- **The 2010 HRSA guidance permitting unlimited contract pharmacies (versus one before), and the contract-pharmacy count now declining to about 31,593 locations mid-2026, a fourth consecutive annual drop:** the [Congressional Research Service on the guidance history](https://crsreports.congress.gov/product/pdf/LSB/LSB11163) and [Drug Channels on the shrinking contract-pharmacy market](https://www.drugchannels.net/2026/06/the-340b-contract-pharmacy-market-in.html) (industry-aligned). The count of restricting manufacturers, roughly thirty to forty-plus, shifts over time; see the [340B Report restrictions tracker](https://340breport.com/trackers/contract-pharmacy-restrictions-tracker/).
- **The two litigation tracks: the D.C. Circuit's May 2024 ruling that manufacturers may impose contract-pharmacy conditions (Novartis Pharmaceuticals Corp. v. Johnson, No. 21-5299), and the state-law circuit split created when the Fourth Circuit blocked West Virginia's law on March 31, 2026 after the Fifth and Eighth Circuits had upheld state laws:** the [D.C. Circuit opinion via Justia](https://law.justia.com/cases/federal/appellate-courts/cadc/21-5299/21-5299-2024-05-21.html) and [analysis of the circuit split](https://www.druganddevicelawblog.com/2026/04/next-stop-scotus-fourth-circuit-creates-split-on-340b-contract-pharmacies.html) (a law-firm blog). Litigation status is as of mid-2026 and evolving.
- **The February 2026 vacatur of HRSA's 340B rebate-model pilot (AHA v. Kennedy, No. 25-cv-600, D. Maine):** the [National Law Review summary](https://natlawreview.com/article/340b-rebate-model-pilot-program-effectively-ends-preserving-upfront-discounts-now) (a law-firm publication). Up-front discounts remain in effect.
- **HRSA oversight weaknesses, about 200 audits a year and only 5 of 20 recommendations implemented, with no confirmation that savings reach patients, and the contested patient-benefit question:** the [Government Accountability Office, October 2025](https://www.gao.gov/products/gao-26-108784) and its earlier [Medicaid duplicate-discount review](https://www.gao.gov/products/gao-20-212). GAO documents gaps and unverifiable assurance, not proven fraud; hospital groups (the American Hospital Association, 340B Health) and manufacturers are advocates on opposite sides and are labeled as such throughout.

- **The investment-portfolio layer** (nonprofit hospital systems holding more than 283 billion dollars in market investments as of 2019; Kaiser Permanente's roughly 9.3 billion dollar 2025 net income, mostly from investments, against about 1.4 billion in operating income and a roughly 73 billion dollar reserve; and Ascension's roughly 15.5 billion dollars in unrestricted cash and investments plus its billion-dollar-plus venture fund): [KFF Health News](https://kffhealthnews.org/health-industry/mission-and-money-clash-in-nonprofit-hospitals-venture-capital-ambitions/) and [Becker's Hospital Review](https://www.beckershospitalreview.com/finance/kaiser-permanentes-9-3b-net-income-draws-scrutiny-six-things-to-know/). These figures describe large nonprofit systems, not the small standalone Critical Access Hospitals and community health centers that also qualify for 340B.

*This post is informational and journalistic, describing a public program and public records. It is not legal, financial, or medical advice. Figures are drawn from government reports, court records, and public data, with throughput totals identified as discounted-purchase volume rather than federal spending; where industry, advocacy, or estimated figures are cited, they are labeled. Litigation described here was accurate as of mid-2026 and continues to evolve.*

---

Canonical HTML: https://jwatte.com/blog/340b-drug-pricing-program/
RSS: https://jwatte.com/feed.xml
JSON Feed: https://jwatte.com/feed.json
Hero image: https://jwatte.com/images/340b-drug-pricing-program.webp